SLU-PP-332 for Exercise Mimetic & Metabolic Enhancement — Performance & Recovery
Experimental ERR agonist that mimics exercise at the molecular level, enhancing mitochondrial function, endurance, and metabolic health without physical training.
Overview
SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRs), specifically targeting ERRα, ERRβ, and ERRγ. It functions as an 'exercise mimetic'—a compound that reproduces many metabolic and physiological effects of aerobic exercise at the cellular level without requiring physical activity. Through ERRα activation, it upregulates PGC-1α and triggers expression of hundreds of exercise-related genes, leading to mitochondrial biogenesis, enhanced fatty acid oxidation, increased energy expenditure, and improved endurance capacity. Preclinical studies show profound metabolic benefits including fat loss, improved glucose tolerance, enhanced exercise capacity, and mitochondrial enhancement. IMPORTANT: No human clinical trials have been published to date—this is an experimental compound with promising preclinical efficacy only.
Indications
- Enhanced exercise endurance and athletic performance (experimental)
- Metabolic optimization and fat loss support
- Mitochondrial biogenesis and function enhancement
- Exercise intolerance due to injury, disability, or aging
- Improved glucose metabolism and insulin sensitivity
- Energy expenditure and metabolic rate optimization
- Complementary support to exercise training programs
Mechanism of Action
Lack of physical activity or inability to exercise leads to mitochondrial dysfunction, metabolic inflexibility, and reduced endurance capacity
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| SLU-PP-332 | 250-500 mcg | Once daily or split into 2 doses | Initial conservative approach based on early practitioner experience |
| SLU-PP-332 | 1-2 mg | Once daily or split into 2 doses | Mid-range dosing for metabolic and performance benefits |
| SLU-PP-332 | 2-5 mg | Once or twice daily | Based on human equivalent dose calculations from mouse studies (100 mg/kg/day mouse = ~8-10 mg/kg human) |
| SLU-PP-332 | 1-2.5 mg | Twice daily (morning and evening) | Matches 12-16 hour half-life for sustained ERR activation |
Evidence Grade
GRADE D
Safety & Contraindications
- EXPERIMENTAL COMPOUND: No human clinical trials published - preclinical data only
- Long-term human safety profile unknown
- Not FDA-approved - available for research purposes only
- Potential concerns about pan-ERR activation and off-target effects
- Monitor liver enzymes and lipid panels during use
- May interact with medications metabolized by CYP3A4
- Contraindicated in known liver disease or cardiovascular conditions
- Discontinue if unusual symptoms develop (fatigue, jaundice, chest pain)
- Not hormonal - does not suppress endogenous testosterone or estrogen
- Consult physician before use, especially with pre-existing conditions